We recently published 10 Shares Explode as Earnings Impress. Veracyte, Inc. (NASDAQ:VCYT) is one of the best-performing ...

Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society, taking place July ...

View the latest Veracyte Inc. (VCYT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Biotechnology company Veracyte (VCYT) is set to replace Triumph Group (TGI) in the S&P SmallCap 600 index prior to the market open on Tuesday, July 29.

Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners ...

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer ...

Veracyte Inc. research and ratings by Barron's. View VCYT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Veracyte’s flagship Afirma Genomic Sequencing Classifier (GSC) was developed with RNA whole-transcriptome-derived sequencing and machine learning technology and helps physicians identify patients with ...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society ...

Tempus AI TEM continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay ...